Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 5:41 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 36 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Omegaven Clear all
Approved For Marketing No phase listed Expanded access

Compassionate Use of Omegaven® for the Treatment of Intestinal Failure Associated Liver Disease in Children

NCT02328768
View directory record Official record
Conditions
Total Parenteral Nutrition-Induced Cholestasis
Interventions
Omegaven
Drug
Lead sponsor
University of Nebraska
Other
Eligibility
Up to 18 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Jan 8, 2024 · Synced Sep 2, 2026, 5:41 AM EDT
Terminated Phase 2 Interventional Results available

Compassionate Use of Omegaven® in the Treatment of Parenteral Nutrition Induced Hepatic Injury

NCT01325584
View directory record Official record
Conditions
Cancer, Hepatic Injury
Interventions
Omegaven
Drug
Lead sponsor
Midwestern Regional Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Zion, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 6, 2018 · Synced Sep 2, 2026, 5:41 AM EDT
Completed Phase 1 Interventional

Safety and Tolerability of Intravenous Fish Oil Lipid Emulsion in Children Undergoing Hematopoietic Cell Transplantation

NCT02512718
View directory record Official record
Conditions
Hematopoietic Stem Cell Transplantation
Interventions
Omegaven, Soybean oil lipid emulsion
Drug
Lead sponsor
Alexandra N. Carey
Other
Eligibility
2 Years to 18 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 21, 2025 · Synced Sep 2, 2026, 5:41 AM EDT
Approved For Marketing No phase listed Expanded access

Compassionate Use of IV Fish Oil for Parenteral Nutrition (PN) Liver Injury

NCT01425567
View directory record Official record
Conditions
Liver Disease
Interventions
Intravenous Lipid Emulsion Comprised of Fish Oil
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
14 Days to 24 Months
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Feb 11, 2019 · Synced Sep 2, 2026, 5:41 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Compassionate Use of an Intravenous Fish Oil Emulsion in Infants With Cholestasis

NCT01601652
View directory record Official record
Conditions
Parenteral Nutrition Associated Cholestasis
Interventions
Omegaven
Drug
Lead sponsor
Arthur J De Lorimier
Other
Eligibility
Up to 1 Year
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jan 26, 2021 · Synced Sep 2, 2026, 5:41 AM EDT
Completed Not applicable Interventional

Omegaven Treatment of Parenteral Nutrition (PN) Induced Liver Injury

NCT01089426
View directory record Official record
Conditions
Liver Injury
Interventions
Omegaven™, Historical Controls
Drug · Other
Lead sponsor
Children's Hospital Los Angeles
Other
Eligibility
Up to 21 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2019
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 5, 2019 · Synced Sep 2, 2026, 5:41 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Use of Omegaven for Treatment With Parenteral Nutrition Associated Liver Disease

NCT04697888
View directory record Official record
Conditions
Parenteral Nutrition-related Hepatitis
Interventions
Omegaven
Drug
Lead sponsor
Children's Mercy Hospital Kansas City
Other
Eligibility
Up to 17 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 10, 2021 · Synced Sep 2, 2026, 5:41 AM EDT
Withdrawn Not applicable Interventional

Compassionate Use of Omegaven IV Fat Emulsion

NCT01323907
View directory record Official record
Conditions
Total Parenteral Nutrition-induced Cholestasis
Interventions
Omegaven IV lipid emulsion
Drug
Lead sponsor
Sivan Kinberg
Other
Eligibility
2 Months to 18 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 5, 2020 · Synced Sep 2, 2026, 5:41 AM EDT
Not listed Not applicable Interventional

Omegaven® as Parenteral Nutrition

NCT02334293
View directory record Official record
Conditions
Cholestasis
Interventions
Omegaven
Drug
Lead sponsor
Carle Foundation Hospital
Other
Eligibility
14 Days to 4 Months
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2013
U.S. locations
1
States / cities
Urbana, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 7, 2015 · Synced Sep 2, 2026, 5:41 AM EDT
Approved For Marketing No phase listed Expanded access

Expanded Access of Omegaven IV Fat Emulsion to Infants and Children With PNALD

NCT02929303
View directory record Official record
Conditions
Total Parenteral Nutrition-induced Cholestasis
Interventions
Omegaven IV lipid emulsion
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
Up to 17 Years
U.S. locations
1
States / cities
Park Ridge, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 30, 2025 · Synced Sep 2, 2026, 5:41 AM EDT
Completed Phase 2 Interventional Results available

Evaluation of Omegaven™ Parenteral Nutrition in Patients With Total Parenteral Nutrition (TPN)-Induced Cholestasis

NCT00826020
View directory record Official record
Conditions
Parenteral Nutrition Associated Liver Disease PNALD, Cholestasis
Interventions
Omegaven™
Drug
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Oct 4, 2023 · Synced Sep 2, 2026, 5:41 AM EDT
Completed Not applicable Interventional Results available

Compassionate Use of Omegaven to Reverse Parenteral Nutrition Induced Cholestasis

NCT01173159
View directory record Official record
Conditions
Cholestasis
Interventions
Omegaven
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
1 Month to 18 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 16, 2020 · Synced Sep 2, 2026, 5:41 AM EDT
Completed Phase 3 Interventional Results available

Omegaven as Alternative Parenteral Fat Nutrition

NCT03662282
View directory record Official record
Conditions
Cholestasis, Cholestasis of Parenteral Nutrition
Interventions
Omegaven
Drug
Lead sponsor
University of South Florida
Other
Eligibility
14 Days and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jul 21, 2020 · Synced Sep 2, 2026, 5:41 AM EDT
Not listed Phase 2 Interventional

Efficacy and Safety of Omega-3 Lipid Therapy in Pediatric Patients With Parenteral Nutrition-Associated Liver Disease

NCT01739517
View directory record Official record
Conditions
Short Bowel Syndrome, Cholestasis
Interventions
Omegaven Therapy
Drug
Lead sponsor
Amarnath, Rathna, M.D.
Individual
Eligibility
Up to 1 Year
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Columbia, South Carolina
Source: ClinicalTrials.gov public record
Updated Dec 2, 2012 · Synced Sep 2, 2026, 5:41 AM EDT
Completed Phase 4 Interventional Results available

Use of Omega-3 Fat Emulsion (Omegaven) in Infants With Parenteral Nutrition Associated Liver Disease

NCT00862446
View directory record Official record
Conditions
Parenteral Nutrition Associated Liver Disease
Interventions
Omegaven
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
Up to 24 Months
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2019
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 4, 2021 · Synced Sep 2, 2026, 5:41 AM EDT
Completed Phase 2 Interventional Results available

Omega-3 Long Chain Polyunsaturated Fatty Acid (LCPUFA) Supplementation in Very Low Birth Weight Infants for The Prevention Retinopathy of Prematurity

NCT02486042
View directory record Official record
Conditions
Retinopathy of Prematurity
Interventions
Omegaven, Standard lipids (primarily omega-6 fatty acids)
Drug · Dietary Supplement
Lead sponsor
University of California, San Diego
Other
Eligibility
Up to 7 Days
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Dec 28, 2022 · Synced Sep 2, 2026, 5:41 AM EDT
No Longer Available No phase listed Expanded access

Omegaven Expanded Access Protocol

NCT02121769
View directory record Official record
Conditions
Parenteral Nutrition Associated Liver Disease
Interventions
Omegaven
Drug
Lead sponsor
St. Luke's Health System, Boise, Idaho
Other
Eligibility
Up to 17 Years
U.S. locations
1
States / cities
Boise, Idaho
Source: ClinicalTrials.gov public record
Updated Apr 9, 2019 · Synced Sep 2, 2026, 5:41 AM EDT
Terminated Phase 2 Interventional Results available

A Safety and Efficacy Study to Determine if Giving Intravenous Fish Oil Helps Children With Liver Disease

NCT00969332
View directory record Official record
Conditions
Cholestasis
Interventions
Omegaven
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
2 Weeks to 18 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2019
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 25, 2020 · Synced Sep 2, 2026, 5:41 AM EDT
No Longer Available No phase listed Expanded access

Compassionate Use of Omegaven IV Fat Emulsion

NCT02477345
View directory record Official record
Conditions
Cholestasis, Liver Disease
Interventions
Omegaven IV
Drug
Lead sponsor
Northwell Health
Other
Eligibility
1 Day to 5 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Staten Island, New York
Source: ClinicalTrials.gov public record
Updated Dec 7, 2017 · Synced Sep 2, 2026, 5:41 AM EDT
Approved For Marketing No phase listed Expanded access

Compassionate Use of Omegaven® in the Treatment of Parenteral Nutrition Associated Hepatic Injury

NCT01412359
View directory record Official record
Conditions
Total Parenteral Nutrition-induced Cholestasis
Interventions
Omegaven®
Drug
Lead sponsor
Jeffrey Rudolph
Other
Eligibility
2 Months to 10 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 23, 2019 · Synced Sep 2, 2026, 5:41 AM EDT
Approved For Marketing No phase listed Expanded access

Intravenous Fish Oils in the Treatment of Parenteral Nutrition Liver Injury

NCT02780193
View directory record Official record
Conditions
Cholestasis, Total Parenteral Nutrition-induced Cholestasis
Interventions
Omegaven
Drug
Lead sponsor
Rush University Medical Center
Other
Eligibility
Up to 18 Years
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 7, 2019 · Synced Sep 2, 2026, 5:41 AM EDT
No Longer Available No phase listed Expanded access

Use of Omega 3 Oil Emulsion for Parenteral Nutrition Associated Cholestasis

NCT02148146
View directory record Official record
Conditions
Cholestasis
Interventions
Omegaven
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
Up to 18 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
2
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jan 11, 2021 · Synced Sep 2, 2026, 5:41 AM EDT
Completed Phase 2 Interventional Results available

Omegaven® in the Treatment of Parenteral Nutrition (PN) Induced Liver Injury

NCT01845116
View directory record Official record
Conditions
Total Parenteral Nutrition-induced Cholestasis
Interventions
Omegaven®
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
4 Weeks to 18 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2020
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 22, 2022 · Synced Sep 2, 2026, 5:41 AM EDT